HER2/PD1 bispecific antibody in IgG4 subclass with superior anti-tumour activities

Clin Transl Med. 2022 Apr;12(4):e791. doi: 10.1002/ctm2.791.

Wendi Chu^{1

2}, Hui Xu^{3

2}, Yanfei Wang^{1

2}, Yongle Xie^{3

2}, Yi-Li Chen⁴, Xiaorong Tan¹, Chenghao Huang⁵, Guifeng Wang^{1

2}, Qi Wang¹, Wenxin Luo⁵, Ningshao Xia⁵, Meiyu Geng^{3

2}, Zuoquan Xie^{3

2}, Chunhe Wang^{1

2

6}

¹ Biotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Bldg#1, 720 Cai Lun Road, Shanghai, 200126, PR China.
² University of Chinese Academy of Sciences, Beijing, PR China.
³ State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai, 200126, PR China.
⁴ Shanghai Mabstone Biotechnology Ltd, Shanghai, PR China.
⁵ State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health and School of Life Science, Xiamen University, Xiamen, PR China.
⁶ Dartsbio Pharmaceuticals Ltd, Zhongshan, PR China.

No abstract available

Publication types